MRX Financial Facts
Loss from discontinued operations, net of income tax benefit: 0Net product revenues: 179.13M
See Full Income Statement
Total liabilities and stockholders' equity: 1.86B
Short Term Investments: 629.81M
See Full Balance Sheet
Medicis Pharmaceutical Corp. (MRX) Earnings
|
Expand Research on MRX
| Next EPS Date | 8/19/26 | EPS Growth Rate | +22.5% |
|---|---|---|---|
| Average EPS % Beat Rate | +8.3% | Revenue Growth Rate | +19.2% |
| Average % Move 1-Wk after EPS | +2.1% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
8/19/26  |
Q226 | N/A | $1.25 | N/A | N/A | $595.88M | N/A | N/A | N/A | ||
| 5/6/26 | Q126 | $1.48 | $1.38 | +$0.10 | $692.3M | $686.37M | N/A |  | | Details | |
| 3/3/26 | Q425 | $1.13 | $0.99 | +$0.14 | $572.1M | $508.62M | N/A | | | Details | |
| 11/6/25 | Q325 | $0.96 | $0.94 | +$0.02 | $484.6M | $475.84M | N/A | | | Details | |
| 8/13/25 | Q225 | $1.02 | $0.93 | +$0.09 | $500.1M | $470.53M | N/A | | | Details | |
| 5/15/25 | Q125 | $0.91 | $0.77 | +$0.14 | $467.3M | $428.46M | N/A | | | Details | |
| 3/6/25 | Q424 | $0.76 | $0.61 | +$0.15 | $415.6M | $370.72M | N/A | | | Details | |
| 11/7/24 |
Q324 | N/A | $0.67 | N/A | N/A | $371.26M | N/A | N/A | N/A |
